It seems that some anti-nAChR positive patients with MG do not harbor pathogenic autoAbs against the extracellular parts of the nAChR or their concentration is under the detection limit of CBA, something that may affect the decision of treatment's strategy. The gene discussed is CHRNA4; the disease is myasthenia gravis.